Bucindolol (MJ-13105-1; MJ-131051) is a β-adrenergic receptor antagonist with the potential to be used for the treatment of chronic heart failure and atrial. Bucindolol is a fourth-generation β-blocker in development for the treatment of CHF. Bucindolol prevented new-onset AF; β1 and α(2c) polymorphisms predicted therapeutic response; and the 47% of patients who were β1389 Arg homozygotes had an enhanced effect size of 74%.

纯度：≥98%

CAS：70369-47-0